134 related articles for article (PubMed ID: 19482477)
1. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel.
Erez R; Segal E; Miller K; Satchi-Fainaro R; Shabat D
Bioorg Med Chem; 2009 Jul; 17(13):4327-35. PubMed ID: 19482477
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Miller K; Eldar-Boock A; Polyak D; Segal E; Benayoun L; Shaked Y; Satchi-Fainaro R
Mol Pharm; 2011 Aug; 8(4):1052-62. PubMed ID: 21545170
[TBL] [Abstract][Full Text] [Related]
3. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
4. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.
Duncan R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1131-48. PubMed ID: 19699249
[TBL] [Abstract][Full Text] [Related]
5. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
Duncan R; Gac-Breton S; Keane R; Musila R; Sat YN; Satchi R; Searle F
J Control Release; 2001 Jul; 74(1-3):135-46. PubMed ID: 11489490
[TBL] [Abstract][Full Text] [Related]
6. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.
Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H
J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967
[TBL] [Abstract][Full Text] [Related]
7. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate.
Miller K; Erez R; Segal E; Shabat D; Satchi-Fainaro R
Angew Chem Int Ed Engl; 2009; 48(16):2949-54. PubMed ID: 19294707
[TBL] [Abstract][Full Text] [Related]
8. Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier.
Sagi A; Segal E; Satchi-Fainaro R; Shabat D
Bioorg Med Chem; 2007 Jun; 15(11):3720-7. PubMed ID: 17416532
[TBL] [Abstract][Full Text] [Related]
9. Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release.
Ferber S; Baabur-Cohen H; Blau R; Epshtein Y; Kisin-Finfer E; Redy O; Shabat D; Satchi-Fainaro R
Cancer Lett; 2014 Sep; 352(1):81-9. PubMed ID: 24614283
[TBL] [Abstract][Full Text] [Related]
10. HPMA copolymer-cyclic RGD conjugates for tumor targeting.
Pike DB; Ghandehari H
Adv Drug Deliv Rev; 2010 Feb; 62(2):167-83. PubMed ID: 19951733
[TBL] [Abstract][Full Text] [Related]
11. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.
Lammers T
Adv Drug Deliv Rev; 2010 Feb; 62(2):203-30. PubMed ID: 19951732
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
[TBL] [Abstract][Full Text] [Related]
13. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
Clementi C; Miller K; Mero A; Satchi-Fainaro R; Pasut G
Mol Pharm; 2011 Aug; 8(4):1063-72. PubMed ID: 21608527
[TBL] [Abstract][Full Text] [Related]
14. N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities.
Zheng ZB; Zhu G; Tak H; Joseph E; Eiseman JL; Creighton DJ
Bioconjug Chem; 2005; 16(3):598-607. PubMed ID: 15898727
[TBL] [Abstract][Full Text] [Related]
15. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo.
Nakamura H; Liao L; Hitaka Y; Tsukigawa K; Subr V; Fang J; Ulbrich K; Maeda H
J Control Release; 2013 Feb; 165(3):191-8. PubMed ID: 23220104
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers.
Ríhová B; Kubácková K
Curr Pharm Biotechnol; 2003 Oct; 4(5):311-22. PubMed ID: 14529421
[TBL] [Abstract][Full Text] [Related]
17. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
18. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
19. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
[TBL] [Abstract][Full Text] [Related]
20. [Selective tumor-accumulation of HPMA copolymer-mitoxantrone conjugates].
Huang Y; Zhang ZR
Yao Xue Xue Bao; 2004 May; 39(5):374-9. PubMed ID: 15338883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
